STERIS plc

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

Is STERIS Stock Underperforming the Nasdaq?

AI-generated analysis

πŸ₯ STERIS plc (STE) is a $21 billion market cap leader in infection prevention products and services.

πŸ”¬ The company offers a diverse portfolio including sterilizers, surgical tables, and equipment management systems.

πŸ“‰ STE stock slipped 20.4% from its 52-week high of $269.44 reached on Jan. 16.

πŸ“ˆ Over the past three months, STE declined 14.8%, underperforming the Nasdaq Composite's 4.7% losses.

πŸ—“οΈ On a six-month basis, shares fell 14.1%, while over the last year they dipped 27.8%.

πŸ“‰ The stock has traded below its 200-day and 50-day moving averages since early March and February respectively.

πŸ’° STE reported Q3 revenue of $1.50 billion, surpassing analyst estimates of $1.48 billion.

πŸ“Š Adjusted earnings per share reached $2.53, meeting Wall Street forecasts for the quarter.

πŸ” Rival Stryker Corporation (SYK) plummeted 7.4% over 52 weeks but outpaced STE with 12.2% six-month losses.

πŸ‘ Wall Street analysts maintain a "Moderate Buy" consensus rating based on nine analyst opinions.

🎯 The mean price target is set at $288.43, suggesting a potential 34.4% upside from current levels.

Bullish Signals
  • Despite recent stock declines, STERIS plc (STE) reported Q3 revenue of $1.50 billion, surpassing analyst estimates of $1.48 billion.
  • The company's adjusted EPS of $2.53 met Wall Street forecasts, demonstrating solid operational performance relative to expectations.
  • Wall Street analysts maintain a consensus 'Moderate Buy' rating for STE based on positive future prospects.
  • The mean price target of $288.43 suggests a 34.4% potential upside from current price levels according to analyst consensus.
  • STE is valued at $21 billion by market cap, underscoring its size, influence, and dominance within the medical devices industry.
Risk Factors
  • STERIS stock slipped 20.4% from its 52-week high of $269.44 achieved on Jan. 16, indicating significant weakness despite market cap exceeding $21 billion.
  • Over the past three months, STE has declined 14.8%, which is a sharp contrast to the Nasdaq Composite's 4.7% losses during the same period, highlighting underperformance relative to the broader market.
  • On a six-month basis, shares of STE fell 14.1%, while underperforming NASX's six-month marginal losses and significantly trailing the index's 27.8% returns over the last year.
  • The stock has been trading below its 200-day moving average since early March and below its 50-day moving average since early February, confirming a bearish technical trend.
  • STE's rival, Stryker Corporation (SYK), experienced even steeper declines over the past six months with 12.2% losses, but STE still underperformed during that same timeframe with larger drops.
Full Analysis
Mentor, Ohio-based STERIS plc (STE) is a large-cap stock valued at $21 billion that specializes in infection prevention products and services within the medical devices industry. The company offers a diverse mix of sterilizers, washers, surgical equipment, lights, and endoscopy accessories, positioning it as a one-stop solution for healthcare providers through its combination of consumables and capital equipment. Despite its market dominance and strong financial fundamentals, recent performance metrics indicate that STE has been underperforming broader market indices like the Nasdaq Composite during the current quarter. STE stock slipped 20.4% from its 52-week high of $269.44, reached on Jan. 16, with a more pronounced decline over the past three months compared to the Nasdaq. The shares have fallen 14.8% in the last quarter against a 4.7% loss for the Nasdaq Composite, dropped 14.1% over six months while the market lost less, and gained 27.8% annually versus STE's 3.5% drop year-to-date. Technical indicators suggest a bearish trend, with shares trading below both the 200-day moving average since early March and the 50-day moving average since early February. Despite these price declines, recent quarterly results on Feb. 4 showed positive financial outcomes. STERIS reported Q3 revenue of $1.50 billion, which exceeded analyst estimates of $1.48 billion, while adjusted earnings per share of $2.53 met Wall Street forecasts. A key rival, Stryker Corporation (SYK), has also struggled recently with 7.4% declines year-to-date and outpaced STE's losses on a six-month basis. Wall Street analysts maintain a "Moderate Buy" consensus rating for STERIS among nine covering firms, citing a mean price target of $288.43 that suggests approximately 34.4% potential upside from current levels.